Products for Research Use Only

RLX

CAT: 0804-HY-116604-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-116604-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness[1].
CAS Number
4425-23-4
Product Name Alternative
PD 139530
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Akt; PI3K
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rlx.html
Smiles
O=C1N2C(CCCCC2)=NC3=C1C=CC=C3
Molecular Formula
C13H14N2O
Molecular Weight
214.26
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Qazi AK, et al. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer. Cancer Lett. 2015 Apr 1;359 (1) :47-56.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported